Helmut R. Salih

17.1k total citations · 1 hit paper
236 papers, 7.9k citations indexed

About

Helmut R. Salih is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Helmut R. Salih has authored 236 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Immunology, 103 papers in Oncology and 69 papers in Hematology. Recurrent topics in Helmut R. Salih's work include Immune Cell Function and Interaction (88 papers), CAR-T cell therapy research (65 papers) and Acute Myeloid Leukemia Research (45 papers). Helmut R. Salih is often cited by papers focused on Immune Cell Function and Interaction (88 papers), CAR-T cell therapy research (65 papers) and Acute Myeloid Leukemia Research (45 papers). Helmut R. Salih collaborates with scholars based in Germany, United States and Switzerland. Helmut R. Salih's co-authors include Hans‐Georg Rammensee, Alexander Steinle, Hans‐Georg Kopp, Theresa Placke, Matthias Krusch, Gundram Jung, Lothar Kanz, Benjamin Joachim Schmiedel, Ludger Große‐Hovest and Tina Baessler and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Helmut R. Salih

226 papers receiving 7.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding

2002 530 citations Helmut R. Salih, Hans‐Georg Rammensee et al. The Journal of Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helmut R. Salih Germany	45	4.6k	3.4k	2.0k	1.8k	566	236	7.9k
Michael Schmitt Germany	43	2.6k 0.6×	3.2k 0.9×	2.6k 1.3×	1.3k 0.7×	683 1.2×	273	7.1k
Motonari Kondo United States	38	5.7k 1.2×	1.7k 0.5×	2.2k 1.1×	1.8k 1.0×	550 1.0×	78	8.4k
Holbrook E. Kohrt United States	45	4.7k 1.0×	4.3k 1.3×	1.3k 0.7×	768 0.4×	543 1.0×	147	7.8k
Robert Sackstein United States	48	2.7k 0.6×	1.8k 0.5×	2.4k 1.2×	2.2k 1.2×	1.1k 1.9×	150	7.5k
Christoph Huber Germany	45	5.0k 1.1×	3.5k 1.0×	3.3k 1.7×	791 0.4×	549 1.0×	155	8.6k
David B. Miklos United States	37	2.6k 0.6×	2.2k 0.6×	1.5k 0.7×	2.1k 1.1×	777 1.4×	224	6.5k
Edus H. Warren United States	43	3.7k 0.8×	2.3k 0.7×	1.3k 0.7×	2.9k 1.6×	641 1.1×	149	7.0k
Roberto M. Lemoli Italy	48	3.1k 0.7×	1.8k 0.5×	2.1k 1.0×	2.9k 1.6×	896 1.6×	239	7.7k
Todd A. Fehniger United States	49	11.6k 2.5×	4.2k 1.2×	1.6k 0.8×	2.0k 1.1×	458 0.8×	189	14.1k
Katayoun Rezvani United States	51	4.9k 1.1×	5.5k 1.6×	2.8k 1.4×	3.6k 1.9×	1.7k 3.0×	216	11.2k

Countries citing papers authored by Helmut R. Salih

Since Specialization

Citations

This map shows the geographic impact of Helmut R. Salih's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helmut R. Salih with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helmut R. Salih more than expected).

Fields of papers citing papers by Helmut R. Salih

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helmut R. Salih. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helmut R. Salih. The network helps show where Helmut R. Salih may publish in the future.

Co-authorship network of co-authors of Helmut R. Salih

This figure shows the co-authorship network connecting the top 25 collaborators of Helmut R. Salih. A scholar is included among the top collaborators of Helmut R. Salih based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helmut R. Salih. Helmut R. Salih is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hagelstein, Ilona, André Koch, Jonas S. Heitmann, et al.. (2024). Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome. International Journal of Molecular Sciences. 25(7). 4126–4126. 6 indexed citations

Hagelstein, Ilona, Latifa Zekri, Gundram Jung, et al.. (2024). Targeting CD276 for T cell-based immunotherapy of breast cancer. Journal of Translational Medicine. 22(1). 902–902. 5 indexed citations

Jung, Susanne, Annika Nelde, Yacine Maringer, et al.. (2024). AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients. Frontiers in Oncology. 14. 1458449–1458449. 3 indexed citations

Bauer, Jens, Jonas S. Heitmann, Yacine Maringer, et al.. (2023). FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion. Zeitschrift für Gastroenterologie. 61(8). e374–e374. 1 indexed citations

Heitmann, Jonas S., Juliane S. Walz, Birgit Federmann, et al.. (2023). Clinical development of the bispecific PSMAxCD3 antibody CC-1.. Journal of Clinical Oncology. 41(16_suppl). 2534–2534. 1 indexed citations

Greve, Gabriele, Geoffroy Andrieux, Pascal Schlosser, et al.. (2023). In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. Leukemia. 37(5). 1018–1027. 2 indexed citations

Hagelstein, Ilona, Tobias Engler, André Koch, et al.. (2023). Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer. International Journal of Molecular Sciences. 24(17). 13156–13156. 5 indexed citations

Märklin, Melanie, et al.. (2023). Crosstalk between NFAT and NFκB Signaling Regulates NK Cell Immunosurveillance. Blood. 142(Supplement 1). 1183–1183.

Bilich, Tatjana, Yacine Maringer, Helmut R. Salih, et al.. (2022). Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort. International Journal of Infectious Diseases. 120. 187–195. 5 indexed citations

10.

Bilich, Tatjana, Annika Nelde, Jonas S. Heitmann, et al.. (2021). T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Science Translational Medicine. 13(590). 92 indexed citations

11.

Zhou, Yanjun, Jonas S. Heitmann, Martina Hinterleitner, et al.. (2021). Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?. Diagnostics. 11(7). 1188–1188. 4 indexed citations

12.

Nuebling, Tina, Martin Hofmann, Ilona Hagelstein, et al.. (2018). The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia. Cancer Immunology Research. 6(2). 209–221. 46 indexed citations

13.

Dörfel, Daniela, Christian Lechner, Simone Joas, et al.. (2018). The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells. Cancer Immunology Immunotherapy. 67(5). 775–783. 8 indexed citations

14.

Bilich, Tatjana, Annika Nelde, Daniel J. Kowalewski, et al.. (2017). Definition and Characterization of a Peptide Warehouse for the Patient-Individualized Peptide Vaccination Study (iVAC-L-CLL01) after First Line Therapy of CLL. Blood. 130. 5346–5346. 2 indexed citations

15.

Raab, Stefanie, Julia Steinbacher, Benjamin Joachim Schmiedel, et al.. (2014). Fc-Optimized NKG2D–Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status. The Journal of Immunology. 193(8). 4261–4272. 30 indexed citations

16.

Venturelli, Sascha, Alexander Berger, Timo Weiland, et al.. (2013). Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2′-Deoxycytidine in Solid Tumor Cells. Molecular Cancer Therapeutics. 12(10). 2226–2236. 86 indexed citations

17.

Schmiedel, Benjamin Joachim, Tina Nuebling, Hans‐Georg Kopp, et al.. (2012). RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia. Cancer Research. 73(2). 683–694. 49 indexed citations

18.

Placke, Theresa, Melanie Örgel, Martin Schaller, et al.. (2011). Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells. Cancer Research. 72(2). 440–448. 350 indexed citations

19.

Baessler, Tina, Matthias Krusch, Benjamin Joachim Schmiedel, et al.. (2009). Glucocorticoid-Induced Tumor Necrosis Factor Receptor–Related Protein Ligand Subverts Immunosurveillance of Acute Myeloid Leukemia in Humans. Cancer Research. 69(3). 1037–1045. 66 indexed citations

20.

Salih, Helmut R., Hans‐Georg Rammensee, & Alexander Steinle. (2002). Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding. The Journal of Immunology. 169(8). 4098–4102. 530 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact